1. Home
  2. VBNK vs CRVS Comparison

VBNK vs CRVS Comparison

Compare VBNK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VBNK
  • CRVS
  • Stock Information
  • Founded
  • VBNK 1980
  • CRVS 2014
  • Country
  • VBNK Canada
  • CRVS United States
  • Employees
  • VBNK N/A
  • CRVS N/A
  • Industry
  • VBNK Commercial Banks
  • CRVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • VBNK Finance
  • CRVS Health Care
  • Exchange
  • VBNK Nasdaq
  • CRVS Nasdaq
  • Market Cap
  • VBNK 370.1M
  • CRVS 305.4M
  • IPO Year
  • VBNK 2021
  • CRVS 2016
  • Fundamental
  • Price
  • VBNK $10.97
  • CRVS $5.75
  • Analyst Decision
  • VBNK Strong Buy
  • CRVS Strong Buy
  • Analyst Count
  • VBNK 4
  • CRVS 4
  • Target Price
  • VBNK $17.50
  • CRVS $15.00
  • AVG Volume (30 Days)
  • VBNK 107.0K
  • CRVS 494.0K
  • Earning Date
  • VBNK 09-04-2025
  • CRVS 08-07-2025
  • Dividend Yield
  • VBNK 0.65%
  • CRVS N/A
  • EPS Growth
  • VBNK N/A
  • CRVS N/A
  • EPS
  • VBNK 0.79
  • CRVS N/A
  • Revenue
  • VBNK $79,960,487.00
  • CRVS N/A
  • Revenue This Year
  • VBNK $13.07
  • CRVS N/A
  • Revenue Next Year
  • VBNK $41.68
  • CRVS N/A
  • P/E Ratio
  • VBNK $13.75
  • CRVS N/A
  • Revenue Growth
  • VBNK N/A
  • CRVS N/A
  • 52 Week Low
  • VBNK $8.51
  • CRVS $2.54
  • 52 Week High
  • VBNK $18.38
  • CRVS $10.00
  • Technical
  • Relative Strength Index (RSI)
  • VBNK 50.19
  • CRVS 65.10
  • Support Level
  • VBNK $10.61
  • CRVS $5.28
  • Resistance Level
  • VBNK $11.29
  • CRVS $5.64
  • Average True Range (ATR)
  • VBNK 0.34
  • CRVS 0.30
  • MACD
  • VBNK 0.06
  • CRVS 0.03
  • Stochastic Oscillator
  • VBNK 73.11
  • CRVS 77.70

About VBNK VersaBank

VersaBank is a Canadian Schedule I chartered bank with a difference. It has 3 operating segments: Digital Banking Canada, Digital Banking USA and DRTC. It's, cloud-based, business-to-business deposit and lending model provides valued-added solutions to Canadian financial intermediary partners, enabling them to focus on growing their own businesses faster and more profitably. It obtains all of its deposits and provides the majority of its loans and leases electronically, with deposit and lending solutions for financial intermediaries that allow them to excel in their core businesses. In addition, leveraging its internally developed IT security software and capabilities, Company established a wholly owned, subsidiary. Geographically located in Canada and USA.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Share on Social Networks: